Dexamethasone Modulates the Cytokine Response but Not COVID-19-Induced Coagulopathy in Critically Ill.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
14 Apr 2023
Historique:
received: 02 03 2023
revised: 29 03 2023
accepted: 05 04 2023
medline: 1 5 2023
pubmed: 28 4 2023
entrez: 28 4 2023
Statut: epublish

Résumé

Severe forms of coronavirus 2019 (COVID-19) disease are caused by an exaggerated systemic inflammatory response and subsequent inflammation-related coagulopathy. Anti-inflammatory treatment with low dose dexamethasone has been shown to reduce mortality in COVID-19 patients requiring oxygen therapy. However, the mechanisms of action of corticosteroids have not been extensively studied in critically ill patients in the context of COVID-19. Plasma biomarkers of inflammatory and immune responses, endothelial and platelet activation, neutrophil extracellular trap formation, and coagulopathy were compared between patients treated or not by systemic dexamethasone for severe forms of COVID-19. Dexamethasone treatment significantly reduced the inflammatory and lymphoid immune response in critical COVID-19 patients but had little effect on the myeloid immune response and no effect on endothelial activation, platelet activation, neutrophil extracellular trap formation, and coagulopathy. The benefits of low dose dexamethasone on outcome in critical COVID-19 can be partially explained by a modulation of the inflammatory response but not by reduction of coagulopathy. Future studies should explore the impact of combining dexamethasone with other immunomodulatory or anticoagulant drugs in severe COVID-19.

Identifiants

pubmed: 37108440
pii: ijms24087278
doi: 10.3390/ijms24087278
pmc: PMC10138864
pii:
doi:

Substances chimiques

Cytokines 0
Dexamethasone 7S5I7G3JQL

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Fondation saint luc
ID : NA

Références

Front Immunol. 2021 Aug 26;12:719023
pubmed: 34512643
N Engl J Med. 2020 Dec 3;383(23):2255-2273
pubmed: 33264547
Crit Care Med. 1985 Oct;13(10):818-29
pubmed: 3928249
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Thromb Res. 2020 Jul;191:145-147
pubmed: 32291094
Microorganisms. 2022 May 08;10(5):
pubmed: 35630429
JAMA. 2021 Apr 27;325(16):1620-1630
pubmed: 33734299
Crit Care. 2020 Dec 14;24(1):696
pubmed: 33317589
Minerva Anestesiol. 2023 Jan-Feb;89(1-2):48-55
pubmed: 36282222
CMAJ. 2020 Jul 6;192(27):E756-E767
pubmed: 32409522
J Formos Med Assoc. 2021 May;120(5):1269-1273
pubmed: 32888840
EBioMedicine. 2022 Jan;75:103812
pubmed: 35033854
Mol Biol Rep. 2022 Jan;49(1):567-576
pubmed: 34643927
Biomolecules. 2022 Jul 27;12(8):
pubmed: 36008932
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Drugs. 2020 Sep;80(13):1267-1292
pubmed: 32696108
Nat Rev Immunol. 2021 May;21(5):319-329
pubmed: 33824483
N Engl J Med. 2021 Aug 26;385(9):790-802
pubmed: 34351721
Biomedicines. 2023 Jan 09;11(1):
pubmed: 36672672
EBioMedicine. 2022 Mar;77:103893
pubmed: 35219085
Nat Rev Immunol. 2013 Jan;13(1):34-45
pubmed: 23222502
BMJ Open. 2017 Sep 27;7(9):e017046
pubmed: 28963294
Rheum Dis Clin North Am. 2016 Feb;42(1):157-76, ix-x
pubmed: 26611557
J Cell Biol. 2010 Nov 1;191(3):677-91
pubmed: 20974816
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
Ann Med. 2021 Dec;53(1):117-134
pubmed: 33095083
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:1076029621993573
pubmed: 33571009
J Immunol. 2007 Feb 1;178(3):1845-51
pubmed: 17237435
Crit Care Med. 2009 May;37(5):1649-54
pubmed: 19325482
JAMA. 2020 Oct 6;324(13):1307-1316
pubmed: 32876695
Front Med (Lausanne). 2022 Jan 17;8:780750
pubmed: 35111777
Cytokine. 2021 Aug;144:155593
pubmed: 34074585
Thromb Haemost. 2001 Nov;86(5):1327-30
pubmed: 11816725
JAMA. 2020 Oct 6;324(13):1317-1329
pubmed: 32876697
JAMA. 2020 Oct 6;324(13):1330-1341
pubmed: 32876694
Science. 2004 Mar 5;303(5663):1532-5
pubmed: 15001782
Ann Intern Med. 2020 Aug 18;173(4):268-277
pubmed: 32374815
J Immunol. 2008 Oct 15;181(8):5490-500
pubmed: 18832706
BMC Infect Dis. 2021 Aug 3;21(1):738
pubmed: 34344353
Intensive Care Med. 2020 Jun;46(6):1089-1098
pubmed: 32367170
N Engl J Med. 2021 Aug 26;385(9):777-789
pubmed: 34351722
Br J Pharmacol. 2006 Jun;148(3):245-54
pubmed: 16604091
Nat Rev Immunol. 2020 Jul;20(7):389-391
pubmed: 32439870
Respir Res. 2022 Jun 3;23(1):145
pubmed: 35659223
Mol Cell Endocrinol. 2011 Mar 15;335(1):2-13
pubmed: 20398732
JAMA Intern Med. 2021 Dec 1;181(12):1612-1620
pubmed: 34617959
Shock. 2021 Jun 1;55(6):700-716
pubmed: 33378321
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
EClinicalMedicine. 2020 Dec;29:100639
pubmed: 33251499
Proc Natl Acad Sci U S A. 2010 Sep 7;107(36):15880-5
pubmed: 20798043
Circulation. 2020 Aug 11;142(6):611-614
pubmed: 32776849

Auteurs

Mélanie Dechamps (M)

Pôle de Recherche Cardiovasculaire (CARD), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.
Department of Cardiovascular Intensive Care, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium.

Julien De Poortere (J)

Pôle de Recherche Cardiovasculaire (CARD), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.

Marie Octave (M)

Pôle de Recherche Cardiovasculaire (CARD), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.

Audrey Ginion (A)

Pôle de Recherche Cardiovasculaire (CARD), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.

Valentine Robaux (V)

Pôle de Recherche Cardiovasculaire (CARD), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.

Laurence Pirotton (L)

Pôle de Recherche Cardiovasculaire (CARD), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.

Julie Bodart (J)

Pôle de Recherche Cardiovasculaire (CARD), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.

Damien Gruson (D)

Department of Clinical Biology, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium.

Marie-Astrid Van Dievoet (MA)

Department of Clinical Biology, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium.

Jonathan Douxfils (J)

Department of Pharmacy, Namur Research Institute for Life Sciences (Narilis), 5000 Namur, Belgium.
Qualiblood, s.a., 5000 Namur, Belgium.

Hélène Haguet (H)

Department of Pharmacy, Namur Research Institute for Life Sciences (Narilis), 5000 Namur, Belgium.
Qualiblood, s.a., 5000 Namur, Belgium.

Laure Morimont (L)

Department of Pharmacy, Namur Research Institute for Life Sciences (Narilis), 5000 Namur, Belgium.
Qualiblood, s.a., 5000 Namur, Belgium.

Marc Derive (M)

Inotrem s.a., 54500 Vandoeuvre-les-Nancy, France.

Lucie Jolly (L)

Inotrem s.a., 54500 Vandoeuvre-les-Nancy, France.

Luc Bertrand (L)

Pôle de Recherche Cardiovasculaire (CARD), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.
Walloon Excellence in Life Sciences and Biotechnology (WELBIO) Department, WEL Research Institute, 1300 Wavre, Belgium.

Pierre-François Laterre (PF)

Department of Intensive Care, Centre Hospitalier Regional Mons-Hainaut, 7000 Mons, Belgium.
Critical Care Coordinating Center (4Cs), 1200 Brussels, Belgium.

Sandrine Horman (S)

Pôle de Recherche Cardiovasculaire (CARD), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.

Christophe Beauloye (C)

Pôle de Recherche Cardiovasculaire (CARD), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.
Department of Cardiology, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH